Product information and disease descriptionPlace of product in therapyDisease description
Diagnosis
11 evidence topics · 6 sources
Systematic literature review of HAE disease burden: diagnostic delay
Guideline recommendation: initial C1-INH functional assay
“We recommend that all patients for whom HAE is suspected undergo an initial assessment with a C1-INH functional assay, as long as it is performed by a specialized laboratory using an accurate, validated method.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“If the C1-INH functional assay is unavailable or unreliable, the diagnosis can still be confirmed through quantitative C1-INH measurement and/or genetic testing for SERPING1.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Laboratory findings: C4, C1-INH antigen, and C1-INH function
“C4 levels are low in 90%–95% of patients with HAE-C1-INH during asymptomatic periods and are almost always low during acute attacks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In HAE type 1, C1-INH antigen levels are reduced, whereas in HAE type 2, they are normal or elevated.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In HAE-C1-INH, functional activity is typically less than 50% of normal levels.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Guideline recommendations: genetic testing and cascade family testing
“We recommend genetic testing for HAE-nC1-INH in patients for whom there is high clinical suspicion of HAE and who have normal C1-INH functional assay results.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We recommend cascade family testing for HAE when an index case is diagnosed, either through C1-INH testing or genetic testing, as appropriate based on age and diagnosis (HAE-C1-INH vs. HAE-nC1-INH).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Diagnostic delay over time
“Fortunately, diagnostic delay in HAE has declined considerably in the last decades, from an average of 21 years in the 1970s to around 7–10 years currently” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Under 40% of patients receive a diagnosis within 1 to 3 years after symptom onset.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Age at diagnosis and diagnoses preceding HAE: Finnish national register
Laboratory findings in HAE with normal C1-INH and acquired C1-INH deficiency
“Results for all 3 of these tests are normal in HAE-nC1-INH and in ACE inhibitor–induced angioedema and decreased in acquired C1-INH deficiency (ie, acquired angioedema [AAE-C1-INH]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“C4, C1-INH antigenic levels, and functional activity are within normal ranges in HAE-nC1-INH and typically reduced in AAE-C1-INH.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of note, negative genetic test results should not be considered definitive for excluding HAE-C1-INH or HAE-nC1-INH.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Clinical features suggesting HAE
“Attacks not accompanied by urticaria, except in cases of HAE-CPN1” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“No response to treatment of attacks with epinephrine, H1-antihistamines, or glucocorticoids” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Positive family history, especially if suggestive of autosomal dominant inheritance” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote